In the world of pharmaceutical stocks, positive data for medicine in the pipeline leads to a spike in the company’s stock price on most occasions, and that is what happened with the HEPA stock on Wednesday.
Hepion Pharmaceuticals Inc (NASDAQ:HEPA) is developing a medicine meant for nonalcoholic steatohepatitis (NASH), which is a form of liver disease, and late Tuesday, the company released positive data from the lab.
Positive Catalyst
The product in question is CRV431, and the lab data was highly encouraging. In the study, CRV431 was used on slices of liver in which liver fibrosis was induced experimentally. Then those slices were treated with CRV431 and four other NASH medicine candidates. The results showed that the extent of fibrosis was controlled to a far greater degree by CRV431 than the other four. This data has shown that Hepion’s medicine could eventually prove to be a breakthrough NASH treatment.
>> IIPR Stock Pops After Third Acquisition with Cresco Labs
It is a highly positive development for Hepion Pharmaceuticals, and the market reacted positively. HEPA stock rallied by as much as 33% to $6.60, and it is likely that the stock is going to be in focus this week.
The Chief Executive Officer of the company, Dr. Robert Foster, spoke about the developments: “CRV431 offers a novel approach to the treatment of fibrosis caused by NASH and possibly other causes of liver injury.”
In addition to that, it is important to point out that a Phase 1 single ascending dose study proved that the product is not only safe but is also well tolerated. The company is continuing to test the product on patients. At this point in time, patients are being administered with CRV431 in an ascending dose study that spans over 28 days. These developments have resulted in the rally in HEPA stock, and investors could do well to track this stock today.
Featured image: DepositPhotos © SergeyNivens
